Patients diagnosed with cancer types known to harbor NTRK gene fusions are potential candidates for larotrectinib treatment. Genetic testing is crucial to identify the presence of the fusion and to determine eligibility. It is particularly beneficial for patients who have exhausted other treatment options or whose cancer has proven resistant to conventional therapies.
